Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

World Heart to complete initial testing soon

This article was originally published in Clinica

Executive Summary

World Heart, a Canadian developer of an artificial heart, expects to complete in vitro and animal testing of its first product, the HeartSaver VAD, by the middle of the year. The company based in Ottawa, Ontario, raised $19 million in its initial public offering last year. The HeartSaver is the first pulsatile ventricular assist device (VAD) designed to be permanently implanted in the chest cavity alongside the natural heart. Pilot production of prototypes and long-term animal testing is expected to begin before the end of the year. Clinical trials are scheduled for 1999.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT084073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel